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Antithrombotic Therapy in the Elderly
Davide Capodanno, MD, Dominick J. Angiolillo, MD, PHD
Jacksonville, Florida
Antithrombotic therapy represents the mainstay of treatment for prevention of recurrent ischemic events in pa-
tients with atherothrombotic disease processes. Although the benefits of antithrombotic pharmacotherapy in the
elderly are well established, the elderly are generally more vulnerable to the adverse effects of antithrombotic
drugs. Such higher vulnerability may be related to distinct pharmacokinetic and pharmacodynamic responses in
the late age of life, during which drug–drug interactions due to polypharmacy further enhance the risk of ad-
verse effects associated with the use of antithrombotic agents. Given that the prevalence of atherothrombotic
disease, as well as diseases with thromboembolic potential, increases exponentially with age and that the el-
derly population is in continuous growth, understanding strategies of antithrombotic management in these pa-
tients is of key importance. The present paper provides an overview of the current available evidence on the use
of antithrombotic therapy in elderly patients with the primary focus on treatment of coronary artery
disease. (J Am Coll Cardiol 2010;56:1683–92) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.04.063t
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rging is a major cardiovascular risk factor, and coronary
rtery disease (CAD) is the most common cause of death in
he elderly (1). Importantly, due to increasing longevity and
eclining fertility, the geriatric population is rapidly expand-
ng in industrialized countries. In 2020, the proportion of
he population age 80 years and above is expected to range
etween 3.7% and 7.5% (2). Antithrombotic therapy repre-
ents a mainstay of treatment in patients with CAD.
lthough the benefits of pharmacotherapy in elderly pa-
ients with CAD are well established, the elderly are
enerally more vulnerable to the adverse effects of anti-
hrombotic drugs. This may be further exacerbated by the
oncomitant presence of other disease processes at high risk
or thromboembolic potential, such as atrial fibrillation,
hich also require dedicated antithrombotic drug regimens.
hysicians are challenged with peculiar pharmacokinetic
nd pharmacodynamic mechanisms of altered drug response
n the late age of life, which are aggravated by other issues,
ncluding multimorbidity and polypharmacy. Therefore,
nderstanding whether a drug should or should not be
rescribed as well as individualizing dosage regimens is
ivotal to balance the safety and efficacy profiles of anti-
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ccepted April 5, 2010.hrombotic drugs when used either solely or in combination.
he present paper provides an overview of the currently
vailable evidence on the use of antithrombotic therapy in
lderly patients, with the primary focus on treatment of
AD manifestations.
iological and Pharmacological
onsiderations in the Elderly
ge-dependent alterations of hemostasis in the elderly are
ummarized in Table 1. Overall, the elderly experience a
hift of the hemostatic balance towards increased clotting
nd decreased fibrinolysis (3). Aging may also lead to
hanges intrinsic to the platelet that are associated with
ncreased platelet reactivity. Increased platelet activity has
een correlated with a higher content of platelet phospho-
ipids, suggesting an age-related increase in platelet trans-
embrane signaling or second messenger accumulation (4).
lthough hemostatic factors vary significantly with age,
dditional factors such as blood stasis and vessel wall
egeneration with endothelial dysfunction play a key role
nd contribute to increased platelet activation and arterial
hrombosis in the elderly (5–7).
Several pharmacological aspects need to be considered in
anaging antithrombotic therapies in elderly people. These
nclude age-related changes in absorption, distribution,
etabolism, and clearance of antithrombotic drugs (Fig. 1).
ince polypharmacy is common in elderly patients, this
xposes them to a greater risk of adverse drug–drug inter-
ctions. In addition to pharmacokinetics, age-related
hanges in pharmacodynamics may also occur, leading to a
eduction of homeostatic mechanisms (3,8). This implies
hat drug reactions may be stronger or drug effects may be
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macokinetic and pharmacodynamic
considerations may, therefore, im-
pact the safety and efficacy of anti-
thrombotic treatment in the elderly,
as described in the following text.
Antithrombotic Therapy
in the Elderly:
General Considerations
Currently, there is no general
consensus about the definition of
elderly, and therefore, to general-
ize findings from different clini-
cal trials is often problematic. In
addition, older patients are fre-
quently excluded from cardiovas-
cular clinical trials. Since current
treatment guidelines have been
developed on the basis of obser-
ations from predominantly younger populations and
ainly provide general considerations that are applicable to
lder patients, the management and outcomes of this
ubgroup is often uncertain. Adding to the paucity of
vidence-based data, safety concerns and economic dispar-
ties also often result in a substantial underuse of antithrom-
otic therapies in older patients (9,10). Further, excess
osing of antithrombotic drugs occurs more frequently in
ulnerable populations, including the elderly (11).
ntiplatelet Therapy
spirin. Although a clear excess of adverse events has been
hown with aspirin even at a lower dosage in studies
nvolving elderly patients (12,13), very few primary or
econdary prevention trials have specifically addressed the
spirin benefit-risk ratio in the elderly population, and
vailable data in old patients are frequently derived from
arge clinical trials in which data are stratified by age. The
agnitude of the absolute benefits and risks of primary
revention with aspirin therapy in specific groups, such as
he elderly, is not fully known. In fact, although patients
ith high baseline thrombotic risk are more likely to benefit
rom aspirin, bleeding complications including stroke and
astrointestinal bleeding are more common in the elderly
nd might counteract the small benefit in those at lower
isk. Therefore, whether aspirin should be prescribed in
rimary prevention remains controversial, and a risk-based
pproach to aspirin prescription has been recommended by
he American College of Cardiology/American Heart As-
ociation (ACC/AHA) guidelines and the U.S. Preventive
ervices Task Force (14,15).
In a meta-analysis from the Antiplatelet Trialists’ Col-
aboration, which pooled data from 195 trials involving
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CAD  coronary artery
disease
GP  glycoprotein
INR  international
normalized ratio
LMWH  low molecular
weight heparin
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial Infarction
UFH  unfractionated
heparinore than 135,000 patients, aspirin use for secondary
s
drevention was associated with a 22% reduction in the risk
f the combined end point of vascular death, myocardial
nfarction, and stroke (16). This relative risk reduction was
hown to be similar among age groups (19.4% vs. 23.1% in
atients older and younger than 65 years of age, respec-
ively), resulting in a greater absolute benefit of aspirin
mong the elderly (4.5% vs. 3.3%), who have a higher than
verage risk of vascular events. Overall, the odds of major
xtracranial bleeding with aspirin was 1.6, but this safety
ssue was far offset by the reduction observed in the ischemic
nd point across all the categories of high risk. Data support
hat low-dose aspirin is as effective as higher doses in
reventing ischemic events but is also associated with a lower
ate of major bleeding and an improved net efficacy to safety
alance (17). The ACC/AHA guidelines, which are applicable
o elderly patients, recommend the use of aspirin, in the
bsence of contraindications, in patients with chronic stable
ngina (18), acute coronary syndrome (ACS), or undergoing
ercutaneous coronary intervention (PCI) (19,20). However,
he rate of use of aspirin still tends to be lower in older people
ith established atherosclerotic disease (21).
Overall, data support the use of aspirin for the secondary
revention of vascular events in elderly patients. Although
urrent guidelines do not recommend dosage modifications
ased on age, a 75- to 150-mg dose of aspirin has shown to
e as effective as higher dosages with a lower risk of
astrointestinal toxicity and bleeding, outlining the poten-
ial for a relevant role of this dosing reduction in elderly
atients, particularly when requiring combination therapy
ith clopidogrel. Evidence supporting aspirin prescription
or primary prevention in elderly is less conclusive, as the
ossibility of a smaller benefit than that observed in second-
ry prevention might not counterbalance the risk of bleeding
ge-Dependent Alterationsf Hemostasis in the ElderlyTable 1 Age-D pen nt Alterationsof Hemostasis in the Elderly
Coagulation proteins
Fibrinogen 1
Factor V 1
Factor VII 1
Factor VIII 1
Factor IX 1
Factor XIII 1
High-molecular weight kininogen 1
Prekallikrein levels 1
Anticoagulant proteins
Antithrombin III 2;1
Protein C  ;1
Protein S  ;1
Tissue factor pathway inhibitor 2;1
Fibrinolytic proteins
Plasmin 2
Plasminogen activator inhibitor-1 1
D-dimer 1
rrows1 and2 indicate an increase and reduction, respectively, of age-related variations in the
erum levels of the proteins involved in hemostasis; equal sign () indicates no change. Sex-related
ifferences are also shown. Adapted, with permission, from Franchini (3).
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November 16, 2010:1683–92 Antithrombotic Therapy in the Elderlyvents. This emphasizes the need for specifically designed
andomized trials of aspirin for primary prevention in
ubgroups of patients at high risk of bleeding and throm-
otic complications, such as the elderly.
denosine diphosphate P2Y12 receptor antagonists. Cur-
ent guidelines recommend clopidogrel (a second-
eneration thienopyridine) as an alternative in aspirin-
ntolerant patients for secondary prevention of recurrent
schemic events (22). Clopidogrel has largely replaced ticlo-
idine (a first-generation theinopyridine), due to its more
avorable safety profile (23). In patients presenting with an
CS and undergoing PCI, guidelines recommend the use
f clopidogrel in addition to aspirin (19,20). No dose
djustment based on age is required for clopidogrel. Al-
hough new P2Y12-inhibiting drugs are on the horizon,
lopidogrel is the most studied and utilized in clinical
ractice. In the CURE (Clopidogrel in Unstable angina to
revent Recurrent Events) trial, the combination of clopi-
ogrel and aspirin was associated with a 20% relative
eduction in the combined ischemic end point (composite of
ardiovascular death, nonfatal myocardial infarction, or
troke) and a 38% relative increase of major bleeding at 1
ear in the overall trial population, as compared with aspirin
lone (24). Compared with younger patients, those older
han 65 years of age showed similar absolute reduction
2.0% vs. 2.2%) and a smaller relative reduction (13.1% vs.
8.9%) of the combined ischemic end point with the
ddition of clopidogrel. Clopidogrel, however, was shown to
e significantly more effective than placebo in both groups.
otably, certain high-risk features that have been associated
ith a greater benefit from clopidogrel, such as a high
Figure 1 Mechanisms Leading to Pharmacokinetic Variations o
Effects of antithrombotic drugs are subjects to age-related pharmacokinetic chang
These may occur at 1 or multiple levels: drug absorption, distribution, metabolismhrombolysis In Myocardial Infarction (TIMI) risk score, arior revascularization, and need for PCI, are frequent
mong older patients (25,26).
In the TRITON–TIMI 38 (Trial to Assess Improvement
n Therapeutic Outcomes by Optimizing Platelet Inhibition
ith Prasugrel–Thrombolysis In Myocardial Infarction 38)
rial, the more potent P2Y12 inhibitor prasugrel (a third-
eneration thienopyridine) was associated with a 19% rela-
ive risk reduction in ischemic events compared with clopi-
ogrel in high-risk ACS patients undergoing PCI (27).
lthough prasugrel was associated with a 32% increased risk
f major bleeding, the net clinical benefit was still in favor of
rasugrel in the overall population. Post-hoc analysis iden-
ified patients at higher risk in whom prasugrel was associ-
ted with harm, such as patients with a prior transient
schemic attack or stroke, and those in whom there was no
et clinical benefit as the ischemic benefit was offset by the
isk of bleeding, including elderly (age 75 years) and low
eight (60 kg) patients. In elderly patients, the net clinical
enefit for the use of prasugrel versus clopidogrel was 0.99
95% confidence interval [CI]: 0.81 to 1.21, p  0.92). In
his cohort, the rates of TIMI major or minor bleeding not
elated to coronary artery bypass grafting were 9.0% and
.9% in the prasugrel and clopidogrel groups, respectively,
hereas fatal bleeding occurred in 1.0% of patients treated
ith prasugrel and 0.1% of patients treated with clopidogrel.
ue to these findings, the use of prasugrel in patients 75
ears of age is generally not recommended. However, accord-
ng to the U.S. Food and Drug Administration (FDA), a
0-mg maintenance dose of prasugrel may still be considered
or use in patients 75 years of age in the absence of
ontraindications (prior transient ischemic attack/stroke or
ithrombotic Drug Effects in the Elderly
learance.f Ant
es.
, and cctive bleeding) if high-risk features, such as either diabetes or
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Antithrombotic Therapy in the Elderly November 16, 2010:1683–92past history of myocardial infarction, are present, where its
ffect appears to be greater than the risk of bleeding. The
ffectiveness of lower maintenance dose (5 mg) in the elderly is
urrently under investigation (NCT00699998).
Clinical data on ticagrelor, the first member of a new class
f reversible P2Y12 receptor antagonists called CPTP (Cy-
loPentylTriazoloPyrimidine), have been recently published
28). In the PLATO (Platelet Inhibition and Patient
utcomes) trial, ticagrelor was associated with a 16%
eduction in ischemic events compared with clopidogrel in
atients with ST-segment elevation ACS intended for
rimary PCI or with non–ST-segment elevation ACS
ntended for an invasive or medical approach (28). There
ere no differences in terms of bleeding according to
ifferent definitions among ticagrelor and clopidogrel
roups, but ticagrelor was associated with a higher rate of
ajor bleeding not related to coronary artery bypass graft-
ng, including more cases of fatal intracranial bleeding.
ompared with younger patients, the group of patients
lder than 65 years of age showed greater absolute (2.8% vs.
.3%) and relative reduction (17.0% vs. 15.0%) of the
schemic end point with the use of ticagrelor, although
icagrelor was shown to be significantly more effective than
lopidogrel in both groups. However, patients older than 75
ears of age showed a similar absolute reduction (1.5% vs.
.8%) and a smaller relative reduction (6% vs. 18%) than
hose younger. In this group, ticagrelor was not shown to be
ignificantly more effective than clopidogrel. No evidence of
ncreased risk of major bleeding was noted across multiple
roups of patients stratified by age. Ticagrelor is still not
pproved for clinical use.
Based on the foregoing, clopidogrel is the current stan-
ard of choice for antiplatelet therapy in combination with
spirin in elderly patients, with no dose adjustment required
ased on age. Prasugrel is currently not recommended in
atients 75 years of age, unless the patient has a history of
iabetes or prior history of myocardial infarction in which
he individual risk of bleeding is offset by the increased risk
f thrombotic complications. Clinical testing with a reduced
ose of prasugrel is ongoing and may lead to changes in
urrent recommendations. No specific recommendations are
et available for ticagrelor.
ntravenous glycoprotein (GP) IIb/IIIa inhibitors. The
CC/AHA guidelines recommend the use of GP IIb/IIIa
nhibitors on top of aspirin and heparin in patients in whom
CI is planned, without modification based on age (19).
owever, the bleeding risk in the elderly with these potent
latelet-inhibiting agents remains a major concern. Three
ypes of GP IIb/IIIa inhibitors are currently approved for
linical use (abciximab, eptifibatide, and tirofiban). Dos-
ng adjustment based on creatinine clearance is recom-
ended only for small-molecule GP IIb/IIIa inhibitors
tirofiban and eptifibatide) which are renally cleared (19).
A subanalysis of the CADILLAC (Controlled Abcix-
mab and Device Investigation to Lower Late Angioplasty
omplications) trial showed that routine abciximab admin- mstration, although safe, was not of major benefit in elderly
atients with acute myocardial infarction undergoing pri-
ary PCI (29). Similarly, data from the ISAR-REACT 2
Intracoronary Stenting and Antithrombotic Regimen:
apid Early Action for Coronary Treatment) trial have
uggested that abciximab as adjunctive therapy in the
ontext of PCI may be of lesser benefit in elderly patients
ith non–ST-segment elevation ACS (30). An age sub-
roup analysis from the PURSUIT (Platelet IIb/IIIa in
nstable angina: Receptor Suppression Using Integrilin
herapy) trial showed that bleeding with eptifibatide was
ost notable (71.3% increased relative risk) in patients older
han 80 years of age, a subgroup also experiencing both
bsolute and relative increase in the rate of death or
yocardial infarction at 30 days with this strategy (31). In
he ESPRIT (Enhanced Suppression of the Platelet IIb/IIIa
eceptor with Integrilin Therapy) trial, patients older than
5 years of age demonstrated a greater absolute (7.2% vs.
.3%) and relative (52.6% vs. 16%) benefit of eptifibatide in
educing the combined end point of death, myocardial
nfarction, or revascularization (32). Since this trial excluded
atients with renal failure, this observation stresses the
mportance of patient selection in the balance of risk and
enefit. Similarly, the PRISM (Platelet Receptor Inhibition
n Ischemic Syndrome Management) and the PRISM-
LUS (Platelet Receptor Inhibition in Ischemic Syndrome
anagement in Patients Limited by Unstable Signs and
ymptoms) trials, assessing the safety and efficacy of tirofi-
an, excluded patients with a creatinine level 2.5 mg/dl
33,34). In these trials, the treatment effect with tirofiban
as similar between younger and older patients. A meta-
nalysis of 6 trials that evaluated the existence of a class
ffect showed that the benefit of GP IIb/IIIa administration
n ACS patients declined with advancing age, with a 4%
onsignificant treatment effect observed in patients 70
ears of age and 62% increased risk of major bleeding (35).
The aforementioned data, in aggregate, outline that the
elative benefit and harm of GP IIb/IIIa inhibitor use varies
cross age strata, with elderly patients experiencing lower
fficacy and disproportionate rates of bleeding compared
ith younger patients. These unfavorable outcomes may be
mproved by careful patient selection and GP IIb/IIIa
nhibitor avoidance in patients who do not require PCI.
mportantly, estimation of creatinine clearance and weight
hould be strictly recommended to avoid overdosing, par-
icularly in the elderly. Dose adjustment is recommended
or eptifibatide and tirofiban in patients with poor renal
unction. In elderly patients receiving GP IIb/IIIa inhibi-
ors, the number of antithrombotic drugs used should be
alanced against the individual risk of thrombotic and
leeding complications.
nticoagulant Therapy
ndirect thrombin inhibitors. Current guidelines recom-
end the use of antithrombin therapy in patients with ACS
a
i
o
a
m
o
y
(
e
t
h
b
a
h
h
c
s
U
p
t
c
S
a
t
t
w
a
d
m
v
t
m
o
f
e
w
D
h
d
p
i
t
e
b
I
P
d
p
C
s
t
n
d
p
i
g
A
c
p
t
p
b
s
a
t
p
c
m
p
F
e
S
d
t
r
w
g
3
t
a
f
i
a
b
f
b
O
G
m
a
m
c
r
w
i
e
o
p
w
a
p
s
fi
t
h
1687JACC Vol. 56, No. 21, 2010 Capodanno and Angiolillo
November 16, 2010:1683–92 Antithrombotic Therapy in the Elderlynd undergoing PCI (19,20). Age-specific dose adjustment
n infusion is currently recommended for enoxaparin. The
nly trial comparing antithrombin therapy versus placebo
nd reporting age subgroup data was the FRISC II (Frag-
in and Fast Revascularization during InStability in Cor-
nary artery disease) trial, but it did not enroll patients 75
ears of age (36). In this study, there was a greater absolute
1.9% vs. 0.8%) and relative (18.4% vs. 16%) reduction in
vents with dalteparin in patients 65 years of age than in
hose 65 years of age. A large observational study of
eparin use in elderly patients failed to demonstrate a
enefit in reducing the 30-day rates of mortality (37).
Trials that directly compared low molecular weight hep-
rin (LMWH) and unfractionated heparin (UFH) provided
eterogeneous results, possibly as a reflection of different
eparins, dose regimens, populations, study designs, and
oncomitant therapies. In addition, in the single trials, age
ubgroup data on the efficacy and safety of LMWH and
FH are generally poorly reported. In the A to Z (38) trial,
atients 65 years of age were more likely to benefit with
he usage of enoxaparin than patients 65 years of age as
ompared with UFH. An age subgroup analysis of the
YNERGY (Superior Yield of the New Strategy of Enox-
parin, Revascularization and Glycoprotein IIb/IIa Inhibi-
ors) trial showed similar efficacy but a consistent trend
oward more bleeding and transfusion rates in older patients
ith non–ST-segment elevation ACS treated with enox-
parin as compared with those treated with UFH (39).
Overall, there is a considerable lack of data to draw
efinitive conclusions about the safety and efficacy of treat-
ent with heparin in the elderly population. Elderly indi-
iduals are prone to bleeding complications and more likely
o have less lean body mass and age-related renal impair-
ent, conditions that are known to be associated with
verdosing. Current guidelines emphasize a dose reduction
or enoxaparin based on age in the setting of ST-segment
levation myocardial infarction (STEMI) and in patients
ith impaired renal function.
irect thrombin inhibitors. Direct thrombin inhibitors
ave some advantages over the heparins, such as lack of
ependence on plasma protein, which results in a more
redictable response and makes them very attractive for use
n the elderly. Bivalirudin has a Class Ib recommendation in
he guidelines for the management of non–ST-segment
levation ACS (19), whereas PCI guidelines recommend
ivalirudin as a Class IIa alternative to UFH and GP
Ib/IIIa antagonists in low-risk patients undergoing elective
CI (20). Bivalirudin has also gained a Class Ib recommen-
ation as a supportive measure for primary PCI (20). A
re-specified age subgroup analysis of the ACUITY (Acute
atheterization and Urgent Intervention Triage Strategy)
tudy conducted in non–ST-segment elevation ACS pa-
ients has recently demonstrated that although there were
o significant differences in efficacy, the benefit of bivaliru-
in in terms of absolute reduction in bleeding events is most
ronounced in patients 75 years of age (40). The positive fmpact of bivalirudin usage on clinical outcomes in nona-
enarians undergoing PCI has also been reported (41).
rgatroban, a direct thrombin inhibitor that has reduced
learance in elderly versus younger volunteers, has shown
romising results when used for thromboprophylaxis or
reatment in heparin-induced thrombocytopenia in elderly
atients (42) or patients with impaired renal function (43).
In summary, direct thrombin inhibitors, in particular
ivalirudin in patients with ACS/PCI have shown favorable
afety profiles in randomized trials, making these drugs very
ttractive for use in the elderly. However, further clinical
esting is needed to clarify the role of these drugs as the
referred anticoagulation strategy for older patients in
linical practice. Dose adjustment and anticoagulant status
onitoring is recommended for bivalirudin in patients with
oor renal function.
actor Xa inhibitors. In patients older than 65 years of age
nrolled in the OASIS-5 (Fifth Organization to Assess
trategies in Acute Ischemic Syndromes) trial, fondaparinux
emonstrated a nonsignificant benefit over enoxaparin for
he combined end point of death, myocardial infarction, or
efractory ischemia (44). A significantly better safety profile
as seen independently from age, but the elderly showed a
reater absolute (2.8% vs. 0.7%) and relative (50.9% vs.
3.3%) reduction of bleeding than younger patients. Pa-
ients with renal dysfunction also showed a marked benefit
s a consequence of lower rates of bleeding (45), although
ondaparinux should be avoided in patients with severe renal
mpairment. In summary, treatment with fondaparinux is
ssociated with similar efficacy in reducing ischemic events
ut less bleeding than LMWH. This feature makes
ondaparinux an appealing treatment strategy in the elderly,
ut more specific data on this subgroup are needed.
ral Anticoagulants
uidelines recommend oral anticoagulant therapy for pul-
onary embolism, atrial fibrillation, mechanical heart valve,
nd valvular heart disease (46), morbidities that are com-
only seen in the elderly population. However, there are
oncerns that elderly individuals may be subject to a greater
isk of hemorrhagic complications accompanying the use of
arfarin or other coumarins. The increased risk of develop-
ng atrial fibrillation as well as CAD with age further
nhances these concerns. In the large REACH (REduction
f Atherothrombosis for Continued Health) registry, the
revalence of atrial fibrillation in patients age 45 years
ith CAD was 12.5% and patients with both CAD and
trial fibrillation were on average 5 years older than those
resenting with CAD alone (47). Schemes developed to
tratify the risk of ischemic stroke in patients with atrial
brillation, such as the CHADS2 (Cardiac Failure, Hyper-
ension, Age, Diabetes, Stroke [Doubled]) score, may be
elpful in identifying patients with CAD who benefit most
rom oral anticoagulation (48).
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Antithrombotic Therapy in the Elderly November 16, 2010:1683–92In general, treatment with vitamin K antagonists under
areful monitoring is associated with a 0.3% to 0.5%
ncreased risk of major bleeding per year compared with
ontrols (49). These rates may be higher in routine clinical
ractice, taking into account that data mainly derive from
ounger cohorts than those observed in real life. In partic-
lar, there is a tendency towards a 2- to 3-fold increase in
leeding and intracranial hemorrhages among elderly pa-
ients (49,50). In addition, physicians are reluctant to
rescribe warfarin in elderly patients deemed at high risk of
alls, due to a 4-fold increased risk of traumatic intracranial
emorrhage compared with other patients (51). These
ssues may underline possible explanations for the substan-
ial underutilization of vitamin K antagonists in the elderly
opulation (52). However, even if elderly individuals have
haracteristics that may place them at higher risk for
leeding, they also have characteristics that make them
ore likely to benefit (53). Importantly, in the BAFTA
Birmingham Atrial Fibrillation Treatment of the Aged)
rial, a randomized comparison of warfarin versus aspirin in
73 patients with atrial fibrillation age 75 years, the yearly
isk of the combined primary end point of stroke, intracra-
ial hemorrhage, or clinically significant embolism was 1.8%
n patients who received warfarin and 3.8% in those who
eceived aspirin (relative risk: 0.48, 95% CI: 0.28 to 0.80,
 0.003) (54).
The dose of oral anticoagulants required to maintain a
herapeutic range expressed as the international normalized
atio (INR) for patients over 60 years of age decreases with
ncreasing age, possibly because of a reduction in the
learance of warfarin with age (55–58). Overall, in elderly
atients, the initial dose of warfarin should not exceed 5 mg,
r even less in patients with a high risk of bleeding, those
ndernourished, those who have liver disease, and those
ho have undergone heart valve replacement surgery (59).
ther factors that may influence the response to anticoagu-
ation in elderly patients include the potential for a greater
umber of other medical conditions and/or concurrent drug
se (57). Consequently, it is advisable to monitor older
atients more frequently in order to maximize their time in
he therapeutic range (60). Sex also influences dose, with
omen requiring less warfarin to maintain a therapeutic
NR than men at an equivalent age (55). A role for genetic
esting in determining the optimal dosage of warfarin has
een advocated (61). Various models for estimating the risk
f major bleeding in patients on vitamin K antagonists have
een developed based on identification of independent risk
actors, including age (62–65). These predictive models may
e an aid in clinical decision-making for long-term manage-
ent of anticoagulant therapy (Table 2).
The combination of aspirin, thienopyridines derivatives,
nd oral antiocoagulation (“triple therapy”) is often used in
atients with permanent atrial fibrillation who undergo
CI, particularly when treated with a drug-eluting stent.
owever, prolonged treatment with a combination of war-arin, aspirin, and clopidogrel has shown to be associated cith a 4- to 5-fold increased risk of bleeding and/or need for
ransfusion at 6 months and a 6- to 8-fold increased risk at
2 months (66,67). Although using a lower dose of aspirin
100 mg) and maintaining an INR within the lower
herapeutic range (INR: 2.0 to 2.5) can reduce the risk of
leeding, definitive conclusions cannot be made as dedi-
ated studies in the elderly are either lacking or underpow-
red (20,68). Therefore, “triple therapy” should be pre-
cribed with caution, and drug-eluting stents should be used
n a more limited manner, particularly in elderly patients
ndergoing PCI who also require oral anticoagulation.
hese findings underscore the need for identifying oral
nticoagulants with a more favorable safety profile than
itamin K antagonists. The RE-LY (Randomized Evalua-
ion of Long-Term Anticoagulation Therapy) trial recently
ompared the effects of warfarin in reducing the risk of
troke or systemic embolism with those of 2 fixed doses of
abigatran in 18,113 patients with atrial fibrillation (69).
abigatran is an oral, direct, competitive thrombin inhibitor
hat is administered twice daily and does not require regular
onitoring. Both dabigatran doses (110 mg twice daily and
50 mg twice daily) were noninferior to warfarin with
espect to the primary efficacy outcome. Moreover, the
50-mg dose of dabigatran was shown to be superior to
arfarin with respect to the primary end point, and similar
n terms of major bleeding risk, whereas the 110-mg dose
as superior to warfarin with respect to the safety outcome.
verall, given the increased risk of developing atrial fibril-
ation with age, the safety profile of dabigatran may repre-
ent an attractive alternative to vitamin K antagonists.
In summary, vitamin K antagonists have shown a proven
enefit in reducing thromboembolic complications in pa-
ients with atrial fibrillation, mechanical valves, and pulmo-
ary embolism, but they are underutilized among elderly
atients, who face the highest ischemic risk. Strategies to
ecrease the bleeding risk need to be aggressively imple-
ented in the elderly. These include control of blood
ressure, interventions to reduce falls, careful monitoring of
NR, vigilant management of excessive anticoagulation, and
se of predictive models. The benefit-risk ratio of triple
ntithrombotic therapy compared with the combination of
spirin and clopidogrel cannot be precisely established in the
lderly due to lack of consistent information. Indeed, novel
ral anticoagulants with a better safety profile than vitamin
antagonists, such as dabigatran, may represent promising
gents in the aging population with atrial fibrillation.
ibrinolytic Therapy
lthough the best reperfusion strategy for elderly STEMI
atients warrants further investigation, general agreement
xists that eligible elderly STEMI patients who receive
eperfusion therapy have a lower risk of death than those
ho receive no reperfusion (70). Bleeding complications, in
articular intracranial hemorrhage, represent the major
oncern with fibrinolytic therapy. Importantly, several in-
Contemporary Bleeding Risk Model for Warfarin-Treated PatientsTable 2 Contemporary Bleeding Risk Model for Warfarin-Treated Patients
Bleeding Score Model
(Ref. #) Score Determinants Score Calculation Score Categories Estimated Risk of Major Bleeding
Outpatient Bleeding Risk
Index (62)
Age 65 yrs
History of stroke
History of gastrointestinal bleeding
Recent myocardial infarction, hematocrit
30%, creatinine 1.5 mg/dl or
diabetes mellitus
Score  [1  age65]  [1  stroke]  [1  GIB]
 [1  other risk factors]
0 risk factors  low risk
1–2 risk factors  intermediate risk
3–4 risk factors  high risk
At 3 months:
Low  2%
Intermediate  5%
High  23%
At 12 months:
Low  3%
Intermediate  12%
High  48%
Kuijer et al. (63) Age
Sex
Malignancy
Score  [1.6  age]  [1.3  female sex] 
[2.2  malignancy]
0  low risk
1–3  intermediate risk
3  high risk
At 3 months:
Low  1%
Intermediate  4%
High  7%
Shireman et al. (64) Age 70 yrs
Sex
Remote bleeding
Bleeding during the index hospitalization
Alcohol or drug abuse
Diabetes
Anemia
Antiplatelet therapy
Score  [0.49  age70]  [0.32  female] 
[0.58  remote bleed]  [0.62  recent bleed] 
[0.71  alcohol/drug abuse]  [0.27  diabetes] 
[0.86  anemia]  [0.32  antiplatelet therapy]
1.07  low risk
1.07–2.18  intermediate risk
2.19  high risk
At 3 months:
Low  0.9%
Intermediate  2%
High  5.4%
HEMORR2HAGES score (65) Prior bleeding
Hepatic or renal disease
Alcohol abuse
Malignancy
Age 75 yrs
Reduced platelet count or function
Uncontrolled hypertension
Anemia
Genetic factors
Excessive fall risk
Stroke
Score  [2  prior bleeding]  [1  hepatic/renal disease] 
[1  alcohol abuse]  [1  malignancy] 
[1  age75]  [1  reduced platelet count/function] 
[1  hypertension]  [1  anemia]  [1  genetic] 
[1  fall risk]  [1  stroke]
0
1
2
3
4
5
Bleeding requiring hospitalization
per 100 patient-yrs:
0  1.9%
1  2.5%
2  5.3%
3  8.4%
4  10.4%
5  12.3%
agen  age n years; GIB  gastrointestinal bleeding.
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ytic therapy (e.g., low weight, blood pressure, prior stroke)
re common among elderly individuals, prompting investi-
ations on mechanical reperfusion in these patients (71).
ubset analyses from trials that randomized patients to
rimary PCI or fibrinolytic therapy suggest that PCI is a
referred strategy in older patients (72–75). The TRIANA
Thrombolysis Versus Primary Angioplasty for AMI in
lderly Patient) trial (NCT00257309), a multicenter ran-
omized trial comparing primary PCI versus a conservative
trategy consisting in fibrinolysis or rescue angioplasty in
atients over 75 years of age has been prematurely inter-
upted due to slow recruitment. Despite this sample limi-
ation, the trial showed a dramatic decrease in recurrent
schemia by primary PCI (0.8% vs. 9.7%, p  0.001) in
lderly patients presenting with STEMI.
The ideal adjunctive antiplatelet and antithrombin ther-
py with fibrinolysis, in addition to aspirin, is also of interest
n the elderly population. Adding a 75-mg maintenance
ose of clopidogrel in STEMI patients was associated with
mortality benefit in a large-scale clinical trial in which
lderly patients were highly represented (76). Although the
tility of a 300-mg clopidogrel loading dose was also
ssociated with improved outcomes in another large-scale
linical trial, elderly subjects (75 years of age) were
xcluded (77). The addition of GP IIb/IIIa inhibitors to
brinolytic therapy is currently not recommended (19,20).
ome studies have demonstrated that lower doses of UFH
78) or enoxaparin (79) may be helpful in ameliorating the
leeding risk associated with fibrinolytic therapy in the
lderly. The attempt to achieve a good balance of safety and
fficacy with reduced-dose fibrinolytic therapy and adjunc-
ive antithrombin therapy has not been shown to be effective
n elderly patients (80,81).
onclusions
he physiological changes that accompany aging have an
mportant impact on the effects of therapeutic agents,
ncluding antithrombotic medications. Given that athero-
hrombotic disease processes increase with age and that the
revalence of the elderly population is continuously grow-
ng, understanding strategies of antithrombotic manage-
ent in this high-risk cohort is of key importance. This is
urther emphasized by the fact that antithrombotic therapy
sed to reduce ischemic events in the elderly is counterbal-
nced by their increased risk of bleeding. Numerous factors
hallenge the identification of the optimal antithrombotic
rug regimens in the elderly. These include factors that may
ffect therapeutic agents in general (e.g., renal function,
epatic metabolism, body mass distribution) as well as
actors more specific to thrombosis and hemostasis (e.g.,
latelet dysfunction, coagulation disorders). The greater risk
f adverse drug–drug interactions due to polypharmacy in
he elderly further enhances these concerns. The lack of
edicated studies performed in the elderly, frequently ex-luded from many large-scale clinical trials, often leads to
ither no recommendations on their most appropriate anti-
hrombotic treatment regimen or sometimes arbitrary as-
umptions. The development of novel antithrombotic
gents with a more favorable safety profile may have a
romising role in this ever-growing population. However,
ore data from large-scale clinical trials and dedicated
tudies in the elderly assessing the safety and efficacy of
ntithrombotic treatment strategies are strongly warranted.
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